Literature DB >> 31321539

Fatigue in patients with vestibular schwannoma.

Dhanushan Dhayalan1, Morten Lund-Johansen2,3, Monica Finnkirk2, Øystein Vesterli Tveiten2,3.   

Abstract

BACKGROUND: Patients with vestibular schwannoma (VS) often complain about tiredness, exhaustion, lack of energy, and strength, but such symptoms of fatigue have scarcely been objectified and analyzed in a VS population. We aimed to characterize fatigue in a cohort of patients with VS and compare such symptoms with a control group.
METHODS: All patients who attended an educational course for patients with VS were surveyed with validated tools for assessment of fatigue (fatigue severity scale), anxiety and depression (hospital anxiety and depression scale), sleepiness (Epworth sleepiness scale), and apathy (Starkstein apathy scale). Quality of Life was assessed with the disease-specific Penn Acoustic Neuroma Quality of Life (PANQOL). Symptom severity was estimated with a visual analog scale (VAS). The results have been compared to a control group consisting of patient companions.
RESULTS: Data from 88 VS patients and 49 controls were analyzed. The controls had similar age and sex distribution as patients. Fifty-seven percent of VS patients had significant fatigue, compared to 25% in the control group. The mean fatigue score was 4.1 for the patients, and 2.8 for controls. Patients with fatigue were more likely to have depression, anxiety, sleepiness, and apathy. No correlation of fatigue was found with age, gender, or treatment modality. Regression analyses revealed depression, apathy, and vertigo to be predictors of fatigue. Fatigue was strongly correlated to QoL.
CONCLUSION: Almost six out of ten VS patients had fatigue, significantly higher than the control group. Interest and focus on fatigue in VS patients can improve the patient's QoL.

Entities:  

Keywords:  Acoustic neuroma; Fatigue; Quality of life; Vestibular schwannoma

Mesh:

Year:  2019        PMID: 31321539     DOI: 10.1007/s00701-019-04003-2

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  28 in total

Review 1.  Systematic review of quality of life in the management of vestibular schwannoma.

Authors:  Andrew Gauden; Philip Weir; Graeme Hawthorne; Andrew Kaye
Journal:  J Clin Neurosci       Date:  2011-10-19       Impact factor: 1.961

2.  Factors associated with symptom-specific psychological and functional impact among acoustic neuroma patients.

Authors:  J E Brooker; J M Fletcher; M J Dally; R J S Briggs; V C Cousins; G M Malham; R J Kennedy; R I Smee; S Burney
Journal:  J Laryngol Otol       Date:  2013-12-19       Impact factor: 1.469

3.  Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls.

Authors:  Matthew L Carlson; Oystein Vesterli Tveiten; Colin L Driscoll; Frederik K Goplen; Brian A Neff; Bruce E Pollock; Nicole M Tombers; Marina L Castner; Monica K Finnkirk; Erling Myrseth; Paal-Henning Pedersen; Morten Lund-Johansen; Michael J Link
Journal:  J Neurosurg       Date:  2015-01-02       Impact factor: 5.115

4.  Measuring fatigue in patients with Parkinson's disease - the Fatigue Severity Scale.

Authors:  K Herlofson; J P Larsen
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

Review 5.  Impact of fatigue on quality of life in oncology patients.

Authors:  G A Curt
Journal:  Semin Hematol       Date:  2000-10       Impact factor: 3.851

6.  Self-Reported Listening-Related Effort and Fatigue in Hearing-Impaired Adults.

Authors:  Sara Alhanbali; Piers Dawes; Simon Lloyd; Kevin J Munro
Journal:  Ear Hear       Date:  2017 Jan/Feb       Impact factor: 3.570

7.  Self-assessed quality of life after acoustic neuroma surgery.

Authors:  Simone A Betchen; Jane Walsh; Kalmon D Post
Journal:  J Neurosurg       Date:  2003-11       Impact factor: 5.115

8.  A dimensional versus a categorical approach to diagnosis: anxiety and depression in the HUNT 2 study.

Authors:  Ingvar Bjelland; Stein A Lie; Alv A Dahl; Arnstein Mykletun; Eystein Stordal; Helena C Kraemer
Journal:  Int J Methods Psychiatr Res       Date:  2009-06       Impact factor: 4.035

9.  Prospective comparison of quality of life before and after observation, radiation, or surgery for vestibular schwannomas.

Authors:  Salvatore Di Maio; Ryojo Akagami
Journal:  J Neurosurg       Date:  2009-10       Impact factor: 5.115

10.  Signs and Symptoms of Acoustic Neuroma at Initial Presentation: An Exploratory Analysis.

Authors:  Robert W Foley; Shahram Shirazi; Robert M Maweni; Kay Walsh; Rory McConn Walsh; Mohsen Javadpour; Daniel Rawluk
Journal:  Cureus       Date:  2017-11-15
View more
  4 in total

1.  Comparing the impact of upfront radiosurgery versus expectation in vestibular schwannoma (the V-REX study): protocol for a randomised, observer-blinded, 4-year, parallel-group, single-centre, superiority study.

Authors:  Dhanushan Dhayalan; Øystein Vesterli Tveiten; Frederik Kragerud Goplen; Monica Katrine Finnkirk; Anette Margrethe Storstein; Eli Renate Gruner; Morten Lund-Johansen
Journal:  BMJ Open       Date:  2021-03-17       Impact factor: 2.692

2.  What determines quality of life in patients with vestibular schwannoma?

Authors:  Ineke M J Pruijn; Wietske Kievit; Mayke A Hentschel; Jef J S Mulder; Henricus P M Kunst
Journal:  Clin Otolaryngol       Date:  2020-12-28       Impact factor: 2.597

3.  Feasibility and safety of an immersive virtual reality-based vestibular rehabilitation programme in people with multiple sclerosis experiencing vestibular impairment: a protocol for a pilot randomised controlled trial.

Authors:  Cristina García-Muñoz; María Jesús Casuso-Holgado; Juan Carlos Hernández-Rodríguez; Elena Pinero-Pinto; Rocío Palomo-Carrión; María-Dolores Cortés-Vega
Journal:  BMJ Open       Date:  2021-11-22       Impact factor: 2.692

4.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.

Authors:  Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.